A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight

Inclusion Criteria: * Have overweight or obesity, but are otherwise overtly healthy. * Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)/square meter (m²), inclusive. * Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening. Exclusion Criteria: * Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have either of the following at screening * A fasting plasma glucose concentration greater than or equal to 126 milligrams (mg)/deciliter (dL) or 7.0 millimoles (mmol)/liter (L), or * Hemoglobin A1…